866-997-4948(US-Canada Toll Free)

Allergic Rhinitis-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 135 Pages

Allergic Rhinitis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Rhinitis-Pipeline Review, H2 2017, provides an overview of the Allergic Rhinitis (Respiratory) pipeline landscape.

Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy runny nose, sneezing, swollen eyelids, itchy mouth, throat, ears.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Rhinitis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 8, 16, 4, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 3 molecules, respectively.

Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Rhinitis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Allergic Rhinitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Allergic Rhinitis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Allergic Rhinitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Rhinitis (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Allergic Rhinitis-Overview 7
Allergic Rhinitis-Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 18
Allergic Rhinitis-Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Allergic Rhinitis-Companies Involved in Therapeutics Development 27
Accolade Pharmaceuticals LLC 27
AFFiRiS AG 27
ALK-Abello A/S 27
AlleCures Inc 28
Allergy Therapeutics Plc 29
ASIT Biotech SA 29
Axikin Pharmaceuticals Inc 30
Chong Kun Dang Pharmaceutical Corp 30
Chrysalis BioTherapeutics Inc 30
Fountain Biopharma Inc 31
GlaxoSmithKline Plc 31
Glenmark Pharmaceuticals Ltd 32
HAL Allergy BV 32
Hisamitsu Pharmaceutical Co Inc 33
Intrommune Therapeutics 33
J Uriach Y Compania SA 34
Laboratorios LETI SL 34
Paradigm Biopharmaceuticals Ltd 34
Sanofi 35
Stallergenes Greer plc 35
Sun Pharma Advanced Research Company Ltd 36
Taiho Pharmaceutical Co Ltd 36
Therabron Therapeutics Inc 37
Xencor Inc 37
Allergic Rhinitis-Drug Profiles 39
(fexofenadine hydrochloride + phenylephrine hydrochloride)-Drug Profile 39
(mometasone furoate + olopatadine hydrochloride)-Drug Profile 40
854-A-Drug Profile 41
Allergen for Allergic Conjunctivitis and Allergic Rhinitis-Drug Profile 42
Allergen for Allergic Rhinitis-Drug Profile 43
Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis-Drug Profile 44
Allergen for Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 45
Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma-Drug Profile 46
Allergen for Asthma and Perennial Allergic Rhinitis-Drug Profile 47
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 48
Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 49
Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 50
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 52
Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis-Drug Profile 53
arabinogalactan-Drug Profile 54
B-244-Drug Profile 55
bepotastine besilate SR-Drug Profile 57
BM-41-Drug Profile 58
CBP-174-Drug Profile 59
CG-201-Drug Profile 60
CPC-888-Drug Profile 61
emedastine difumarate-Drug Profile 62
FB-825-Drug Profile 63
gp-ASIT-Drug Profile 64
GSK-2245035-Drug Profile 68
hdm-ASIT-Drug Profile 69
KR-62980-Drug Profile 71
Lactococcus lactis G121-Drug Profile 72
levocabastine hydrochloride + mometasone furoate-Drug Profile 73
mometasone furoate-Drug Profile 74
Monoclonal Antibody for Seasonal Allergic Rhinitis-Drug Profile 75
nasapaque-Drug Profile 76
NVP-1703-Drug Profile 77
pentosan polysulfate sodium-Drug Profile 78
Pollinex Quattro Tree-Drug Profile 82
rag-ASIT-Drug Profile 84
rupatadine-Drug Profile 85
short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT-Drug Profile 86
Small Molecule for Allergic Rhinitis-Drug Profile 87
Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases-Drug Profile 88
Small Molecules for Respiratory Disorders-Drug Profile 89
Small Molecules for Seasonal Allergic Rhinitis-Drug Profile 90
Small Molecules to Antagonize H1 and H3 Receptor for Allergic Rhinitis-Drug Profile 91
Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis-Drug Profile 92
standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract-Drug Profile 93
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine-Drug Profile 96
STG-120-Drug Profile 101
SUN-0597-Drug Profile 102
SYM-001-Drug Profile 104
TAS-205-Drug Profile 105
TO-206-Drug Profile 106
Vaccine for Asthma and Allergic Rhinitis-Drug Profile 107
Vaccine to Target IgE for Allergic Rhinitis and Asthma-Drug Profile 108
XmAb-7195-Drug Profile 109
Zafi-3-Drug Profile 111
Allergic Rhinitis-Dormant Projects 112
Allergic Rhinitis-Discontinued Products 119
Allergic Rhinitis-Product Development Milestones 121
Featured News & Press Releases 121
Appendix 130
Methodology 130
Coverage 130
Secondary Research 130
Primary Research 130
Expert Panel Validation 130
Contact Us 130
Disclaimer 131

List of Tables
Number of Products under Development for Allergic Rhinitis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Allergic Rhinitis-Pipeline by Accolade Pharmaceuticals LLC, H2 2017
Allergic Rhinitis-Pipeline by AFFiRiS AG, H2 2017
Allergic Rhinitis-Pipeline by ALK-Abello A/S, H2 2017
Allergic Rhinitis-Pipeline by AlleCures Inc, H2 2017
Allergic Rhinitis-Pipeline by Allergy Therapeutics Plc, H2 2017
Allergic Rhinitis-Pipeline by ASIT Biotech SA, H2 2017
Allergic Rhinitis-Pipeline by Axikin Pharmaceuticals Inc, H2 2017
Allergic Rhinitis-Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
Allergic Rhinitis-Pipeline by Chrysalis BioTherapeutics Inc, H2 2017
Allergic Rhinitis-Pipeline by Fountain Biopharma Inc, H2 2017
Allergic Rhinitis-Pipeline by GlaxoSmithKline Plc, H2 2017
Allergic Rhinitis-Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
Allergic Rhinitis-Pipeline by HAL Allergy BV, H2 2017
Allergic Rhinitis-Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2017
Allergic Rhinitis-Pipeline by Intrommune Therapeutics, H2 2017
Allergic Rhinitis-Pipeline by J Uriach Y Compania SA, H2 2017
Allergic Rhinitis-Pipeline by Laboratorios LETI SL, H2 2017
Allergic Rhinitis-Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017
Allergic Rhinitis-Pipeline by Sanofi, H2 2017
Allergic Rhinitis-Pipeline by Stallergenes Greer plc, H2 2017
Allergic Rhinitis-Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Allergic Rhinitis-Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017
Allergic Rhinitis-Pipeline by Therabron Therapeutics Inc, H2 2017
Allergic Rhinitis-Pipeline by Xencor Inc, H2 2017
Allergic Rhinitis-Dormant Projects, H2 2017
Allergic Rhinitis-Dormant Projects, H2 2017 (Contd..1), H2 2017
Allergic Rhinitis-Dormant Projects, H2 2017 (Contd..2), H2 2017
Allergic Rhinitis-Dormant Projects, H2 2017 (Contd..3), H2 2017
Allergic Rhinitis-Dormant Projects, H2 2017 (Contd..4), H2 2017
Allergic Rhinitis-Dormant Projects, H2 2017 (Contd..5), H2 2017
Allergic Rhinitis-Dormant Projects, H2 2017 (Contd..6), H2 2017
Allergic Rhinitis-Discontinued Products, H2 2017
Allergic Rhinitis-Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures
Number of Products under Development for Allergic Rhinitis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *